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From Pulmonary Rounds at Stanford
University School of Medicine. This
has been edited by Doctors Joseph
Cummiskey, Andrew Newman, Nor-
man Lewiston and Eugene D. Robin.
JOSEPH CUMMISKEY, MD:* This morning we plan
to discuss the management of two patients with
Rendu-Osler-Weber syndrome, and also to discuss
the use of nuclear isotope scanning in this disease
and in estimating pulmonary vascular shunts. A
33-year-old woman, a divorced mother of two,
came to the Palo Alto Medical Clinic. When she
was 22 years old, left hemiplegia and aphasia
developed suddenly, and cleared in three to four
days. She was taking birth control pills at that
time and this was discontinued. Findings on
carotid arteriography were inconclusive. Twelve
months later, hemoptysis, blood in the feces,
dyspnea, poor vision and dizziness developed. No
cause was found, but these manifestations cleared
spontaneously. She resumed using birth control
pills.
EUGENE D. ROBIN:t A condition that appeared
to be thrombotic disease involving the central
*Fellow in Respiratory Disease.
tProfessor of Medicine and Physiology, Division of Respiratory
Medicine.
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nervous system developed in this patient and
subsequently arteriovenous communications were
demonstrated. How should the differential diag-
nosis be approached? Is it clear that the original
episode was cerebral thrombosis related presum-
ably to the use of birth control pills? The cerebral
vascular disease in this patient could be related
to many disorders which produce focal abnormal-
ities of the central nervous system. A diffuse
approach to differential diagnosis becomes almost
unmanageable because anything is possible.
To be orderly in one's thinking and given two
events that can be connected by a single diag-
nosis, one should favor the single diagnosis rather
than assuming that the two events are uncon-
nected. A philosophical approach which is useful in
differential diagnosis is known as Ockham's razor.
William of Ockham, a 14th century British philos-
opher, was a nominalist, that is, a believer in the
theory that there are no universal essences in
reality. Ockham's razor states that the fewer hy-
potheses required to explain several phenomena,
the more likely it is that a correct one will be se-
lected. That is how the word razor comes in-one
24 JULY 1979 * 131 * 1
Refer to: Cummiskey J, Robin ED, Goris M, et al: Pulmonary
arteriovenous communications in the lung-Stanford Uni-
versity School of Medicine Pulmonary Rounds (Specialty
Conference). West J Med 131:24-35, Jul 1979
PULMONARY ARTERIOVENOUS COMMUNICATIONS
shaves the number of hypotheses. The application
of Ockham's razor to medicine dictates that a dif-
ferential diagnosis should be as tight and econom-
ical as possible. The physicians caring for this
patient used Ockham's r-azor as follows: The use
of birth control pills leads to local thromboses,
causing cerebrovascular disease. This is logical
because there is substantial evidence that the use
of the pill does lead to localized vascular disease,
including vascular disease of the brain. Can an
alternative hypothesis be given involving arterio-
venous (A-V) fistulae?
GEORGE CAUGHEY: * There may have been a brain
hemorrhage because of an A-V malformation in
the brain.
DR. ROBIN: The thesis would be that A-V malfor-
mations lead to cerebral hemorrhage. These vas-
cular malformations are known to be quite thin
walled and often bleed (hence the term hemor-
rhagic). Cerebral hemorrhage is unlikely; the
effects of intracerebral hemorrhage tend to be
devastating even when bleeding in minor. She
recovered completely in three days. Since this is
a pulmonary conference can you think of a hy-
pothesis by which pulmonary A-V fistulae could
give rise to cerebrovascular lesions?
GEORGE CAUGHEY: There might have been an
embolic event because any thrombus or embolism
arising in the right side of the heart could pass
through the lung.
DR. ROBIN: Good. With A-V fistulae in the lung,
the filter function of the pulmonary capillaries
which are about 8 micra in diameter is lost. One
possibility is that there were A-V fistulae in the
patient's lungs that permitted an embolus arising
on the right side to traverse sequentially pulmo-
nary veins, left atrium and the systemic circula-
tion to the brain-so-called paradoxical emboli.
This discussion may not be as tangential as it
sounds because Dr. Goris is going to tell us that
he uses paradoxical emboli to detect and quanti-
tate the degree of right-to-left shunting in such
patients.
DR. CUMMISKEY: Is there not another cause for
a cerebral vascular accident (CVA) in this type of
case, thrombus formation from increased blood
viscosity secondary to the polycythemia of chronic
hypoxia?
DR. ROBIN: Is that an acceptable application of
*Visiting Medical Student
Ockham's razor? This requires several extra hy-
potheses. You add both hypoxemia and eryth-
rocytosis. Both are possible; however, not all
pulmonary A-V fistulae give rise to substantial
hypoxia and secondary polycythemia.
MICHAEL GORIS, MD:t There is another consid-
eration which is purely statistical. Here is some-
body who at age 24 has had three CVA'S, which
could be emboli. Without A-V fistulae to transmit
pulmonary emboli, many of these might have been
asymptomatic. However, with pulmonary A-V
fistulae, some of these became clinically apparent
as brain emboli.
DR. ROBIN: Your point is a good one, and raises
a basic issue. I believe that normal people have
pulmonary emboli frequently. Trapping emboli is
one of the important functions of the lung. Small
pulmonary capillaries trap particulates entering
the venous circulation. These pulmonary emboli
may account for the 5 percent incidence of per-
fusion defects in perfectly normal people.' I can
visualize in our patient, then, small showers of
paradoxical emboli, one of which happened to
involve a critical area of the brain and became
clinically manifest. When everything is known
about pulmonary emboli, I believe one of the
concepts that will emerge is that pulmonary em-
bolism in a sense is a normal process. Most
emboli are relatively small, and do not produce
the clinical disorder that we call pulmonary
embolism.
DR. CUMMISKEY: The patient began to take birth
control pills again and again a left hemiplegia
developed. She stopped taking the pills and hemi-
plegia cleared in a week, and again it was assumed
that the vascular disease was related to birth
control pills. At that time, she was admitted to
the Jewish Hospital in Brooklyn. Hematocrit was
55 percent and hemoglobin was 18 grams per dl.
The electrocardiogram was normal. An x-ray
study of the chest showed multiple circular lesions
in the right lower lobe and left lower lobe and
one lesion in the right upper lobe which appeared
vascular on tomography. Cardiac catheterization
showed normal right heart pressures; cardiac out-
put, 6.7 liters per minute; cardiac index, 3.6.
Arteriovenous oxygen difference was 4.1 volume
percent; arterial oxygen pressure (Po2), 59 torr;
pH, 7.48; arterial carbon dioxide pressure (Paco2),
30 torr on room air. On pulmonary angiography
tAssociate Professor of Nuclear Medicine.
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multiple pulmonary A-V fistulae were shown in
the left lower lobe and the right middle lobe. In
the right lower lobe there were three A-V fistulae
and one fistula in the right upper lobe. Resection
was carried out at that time, with removal of the
left lower lobe fistula. Then the left lingular
fistula was removed with a subsegmental resection.
JAMES THEODORE, MD:* Do you think that is a
curative procedure when dealing with large A-V
fistulae? Do you think that once they have re-
moved some of the fistulae, there will be no
more problems?
DR. CUMMISKEY: That is a loaded question. If
you knew she had Rendu-Osler-Weber syndrome,
the answer would be no.
DR. THEODORE: Let's just stay with A-V fistula.
DR. CUMMISKEY: If it was congenital A-V fistula
and you removed all of the fistulae, it might be a
curative procedure.
DR. THEODORE: That is hard to say. There are a
number of circumstances in which they are mul-
tiple. When larger fistulae predominate there is
always the possibility that the small ones which
were relatively inapparent may become more ap-
parent with time. Although surgical operation is
the procedure of choice under such circumstances,
there is always the possibility that there will be
recurrence.
DR. CUMMISKEY: But looking through the litera-
ture on A-V malformation, I have seen more than
six reports showing that removal of the A-V mal-
formation is curative.2
DR. THEODORE: I am not saying patients are not
cured of symptoms at that time. The point I am
trying to make is that there is always a possibility
that another one may develop later. I cannot give
you the actual percentages.
DR. ROBIN: Recur?
DR. THEODORE: They have probably been there
all along.
DR. ROBIN: The Rendu-Osler-Weber lesions
represent, as far as I know, a congenital malfor-
mation. My impression of the disease is-and if
I am wrong tell me-that persons with the Rendu-
Osler-Weber syndrome are born with a preformed
package of A-V communications.
*Associate Professor of Medicine.
PATRICIA LYNNE-DAVIES, MD:T Are they fully
functional though? If in a patient there were two
or three which were contributing to a major extent
to hypoxemia and which were resected, is it pos-
sible that for the next few years some of the
remaining communications by redirection of flow
might have a more profound effect?
DR. ROBIN: That is an intriguing idea. It appears
reasonable to consider that the regulation of flow
through A-V fistulae is a dynamic process. There-
fore, long-term alterations of pressure-flow rela-
tions might alter the contribution of shunts to
hypoxemia and might create the impression of
formation of new communications.
DR. THEODORE: I did not mean to imply that new
ones were forming either in this circumstance or
when there are isolated pulmonary AV fistulae.
DR. ROBIN: Let me say that I think that surgical
operation, when possible, is by far the best ap-
proach for patients who have pulmonary A-V
fistulae.
DR. CUMMISKEY: Well, that obviously was the
thought in this case, as well. Now the question
comes up as to how often reoperation should be
considered? There was moderate relief of symp-
toms with surgical therapy, and there was no
further hemoptysis in this patient after the pro-
cedure until the age of 28. Then a left CVA
developed. This time she was not taking birth
control pills, which would argue against your feel-
ing, Dr. Robin, that the birth control pills were
contributing to the development of thrombosis.
DR. ROBIN: That was not my conclusion. I sug-
gested that given several possibilities for disease
in the brain, I would have picked either A-V com-
munication with hemorrhage or an A-V fistula in
the lung with paradoxical emboli. Then Dr. Goris
asked if it was possible that there were numerous
pulmonary emboli. I answered that this was pos-
sible and that birth control pills might have accel-
erated that process.
S. J. SALFEN, MD: t Is it not a fact that the
Rendu-Osler-Weber syndrome often presents as a
cerebral vascular accident, not for any of those
reasons but rather because of a brain abscess from
the presumed pre-existing A-V malformation?
DR. ROBIN: The literature I have seen does not
tAssociate Professor of Medicine.
tFellow in Respiratory Disease.
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emphasize the complication of brain abscess as it
does in patients with right to left congenital heart
disease. I, therefore, thought that the reason there
may be infection as a presenting sign, is that the
filter function of the lungs is lost, and bacteria in
the bloodstream find access to the brain.
ALLAN HANCE, MD: * It must be an infected
thrombus.
DR. THEODORE: Without even getting into the
specifics of the disease, endarteritis or some kind
of infection is always a possibility with any kind
of vascular abnormality. I am surprised that with
these patients it does not occur more often.
DR. ROBIN: The clinical pearl that I am aware
of is that patients with tetralogy of Fallot and
with pseudotruncus arteriosus not uncommonly
present with brain abscess. This manifestation may
be the first clue that congenital cyanotic heart dis-
ease is present. I am unaware that the same fre-
quency has been noted in patients with pulmonary
A-V fistulae. If this is true, then I think one of
the mechanisms might involve the entry of bac-
teria into the left side of the circulation.
DR. CUMMISKEY: The patient maintains that in
1972, after the third episode of CVA, she diag-
nosed hereditary hemorrhagic telangiectasia in
herself and her family. Karen Hamilton, a medical
student, provided a family tree. The mother of our
patient had severe epistaxis; her maternal grand-
mother had hemorrhagic telangiectasia, and now
her two children-a daughter aged 7 and a son
aged 10-have telangiectasia on their skin and
mucous membranes, but are asymptomatic. The
patient was next seen, in Ohio, in 1972 because
of increasing dyspnea and cyanosis. The hemo-
globin value was 16.4 grams per dl. An electro-
cardiogram was normal. Liver and brain scans
were normal. Lung scan was normal. Cardiac
catheterization and pulmonary angiograms showed
numerous A-V fistulae in the left lower lobe, pos-
terior segment, and the right, middle and right
upper lobe, anterior and posterior segments. It
was decided not to operate because of the mul-
tiple fistulae and because there was uncertainty
about which to deal with. Bronchoscopy was done
in 1975. The indications are not clear, but the
findings were negative.
DR. ROBIN: One reason might be the possibility
*Fellow in Respiratory Disease.
(with recurrent hemoptysis) of telangiectasia in
the bronchial mucosa which are surgically treat-
able. Surgical therapy may control hemoptysis.
DR. CUMMISKEY: That brings us to the present,
when the patient went to the Palo Alto Clinic.
One week after the patient was first seen, low
right anterior and posterior chest pain developed.
Blood pressure was 90/60 mm of mercury; pulse,
65 and regular; respirations, 60; temperature,
36°C (96.80F). Telangiectasia of the mouth,
lips, face and anterior chest; moderate clubbing,
and slight cyanosis were noted. Examination of
the chest found decreased excursion on the right,
dullness in the right base with no friction rub.
The S-2 was widely split and the P-2 was greater
than A-2. An x-ray film of the chest showed right
pleural effusion. Laboratory studies gave the fol-
lowing values: leukocyte count, 12,000 with 12
percent bands; hematocrit, 49 percent; hemo-
globin, 16.7 grams per dl. Pao2 was 60 torr on
35 percent oxygen, pH was 7.47, Paco2 was 32
and bicarbonate was 23.
The patient was acutely ill. She was admitted
with a diagnosis of possible hemothorax, versus
pulmonary embolism. Thoracentesis showed
bloody pleural fluid. A pneumothorax developed
and a chest tube was placed. When the pneu-
mothorax had resolved, pulmonary function tests
were done. The results were interpreted as show-
ing mild restrictive disease; possibly surgical re-
section could give rise to these changes.
DR. LYNNE-DAVIES: We could say it is mild re-
strictive disease consistent with a history of sur-
gical resection, but I think it is an excellent
example of what you find if you resect what in
mechanical terms is normal lung tissue, because
all lung volumes are reduced in the same pro-
portion with the result that the residual volume
and the expiratory reserve volume are maintained
within normal limits.
DR. THEODORE: It might be better to use the
terms restrictive defect under the circumstances.
ANTONIUS VAN KESSEL, BS: t What about the
effect of pleural disease on the lung volumes?
They are so different from normal values-the
vital capacity and the total volume are about half
normal.
DR. LYNNE-DAVIES: I do not know whether the
tDirector, Pulmonary Function Laboratory.
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hemoglobin was still elevated or not. I suspect it
was at least on the high side of normal.
DR. CUMMISKEY: At that time the hematocrit was
elevated. At present the hematocrit is normal
(41 percent).
DR. LYNNE-DAVIES: The diffusion capacity is
now measured at 100 percent in spite of a degree
of restriction which is about 30 percent. I assume
that, other things being equal, this means other-
wise it would have come out higher than 125
percent-which is acceptable, particularly in the
light of the minor degree of polycythemia.
DR. ROBIN: The discussion concerns the fact that
among other things the measured diffusing capac-
ity (DLCO) is proportionate to the amount of
hemoglobin available to take up carbon monoxide.
Many laboratories correct diffusing capacity to
a normalized hemoglobin so that the DLCO pro-
vides an estimate of diffusing capacity related
purely to lung function.
DR. CUMMISKEY: When we first saw the patient
(February 1978), blood gas determinations and
other studies were carried out with the patient
breathing room air under four conditions-supine,
standing, exercise and sitting (Table 1). The
Pao2 supine decreased from 61 to 50 torr after
the patient had stood for ten minutes. This was
a definite drop in the Pao2 which we felt was due
to shunting of more blood through the bases than
through the upper lobes of the lung.
DR. ROBIN: That would be true only if the A-V
fistulae were largely localized to the bases. Dr.
James Phillips saw a classic case at the University
of Arkansas. The patient had a single, large pul-
monary A-V fistula located in the apex of the left
lung. The major drop in Pao2 occurred when the
patient was placed in the Trendelenburg position
and improved greatly when the patient sat up
(personal communication).
DR. CUMMISKEY: In the Trendelenburg position,
there was the greatest shunt? How about the
supine compared with the upright?
DR. ROBIN: I do not believe Phillips carried out
studies in this case with the patient in the upright
position.
DR. CUMMISKEY: Would there be a gradation
going down toward the worst value when the pa-
tient was in the Trendelenburg position?
TABLE 1.-Changes in Blood Gas Values and Shunt
With Changes in Position and Exercise.
Note Progressively Severe Orthodeoxia With Changes
From the Supine to Standing Position
pH PCO2 HCO3 PO. FiO2
Supine ..............
Standing for 10 minutes
Exercise (6.5 minutes
at 3.5 mph,
slope 5 percent) ....
Sitting for 20 minutes
after exercise .......
7.46 31 21.9 61 room air
7.45 30 20.8 50 room air
7.38 27 15.9 48 room air
7.44 29 19.6 55 room air
Shunt Study with Positional Chanzges
Supine .............. 7.46 27 18.8 273 100%
Sitting .............. 7.44,29 19.3 120 100%
Standing ............ 7.44 29 19.5 78 100%
DR. ROBIN: The standing position is really differ-
ent than the sitting position, and I prefer to dis-
cuss that later. In some of the cases that Dr. Goris
and I studied, for example, there was an addi-
tional further fall in oxygen pressure when patients
stood, compared with when they were sitting. This
suggests that it is not only gravitational effects on
shunt flow that determines the Pao2.
DR. CUMMISKEY: We also studied the effects of
exercise on the patient. The Pao2 fell a little
further on exercise, though not significantly. After
sitting for 20 minutes after exercise, the. Pao2
was 55 torr. We then carried out a 100 percent
oxygen study: in the supine position the Pao2
was 273, in the sitting position it was 120 and
when she stood up it was 78 torr indicating a
large shunt that increased progressively from
supine to sitting to standing (Table 1). Dr. Robin,
would you comment on these data?
DR. ROBIN: The changes in Po2 and shunt are
so large that they must reflect true alteratidns in
oxygen exchange. Decreased oxygen saturation in
the upright versus supine position has been called
orthodeoxia.3 It should be emphasized that cal-
culations of shunt without determining the value
of mixed venous oxygen under these conditions
are not accurate. Changes in position may well
cause changes in cardiac output and influence
mixed venous oxygen saturation. Technically,
therefore, the shunt calculations are not satisfac-
tory. Moreover changes in position may affect
both the volume of flow through the shunt as well
as the oxygen content of the blood flowing through
the shunt. The findings in this case show the de-
velopment of true orthodeoxia. This can be ex-
plained by preferential increase in shunt flow.
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However, the further decrease in oxygen pressure
in the standing position cannot be so explained.
One possibility is that standing is associated with
loss of fluid into the tissues leading to a fall in
cardiac output, reducing mixed venous oxygen
content which then reduces Pao2 because of the
reduced oxygen content of mixed venous blood
going through the shunt vessels.4
DR. CUMMISKEY: At that stage, then we went on
to do a lung perfusion scan with whole body
counting in the standing position. This showed a
shunt of 35 percent of the-cardiac output.
DR. ROBIN: Dr. Goris, what we would really like
to come out of this conference, among other
things, is an appreciation for the errors in estimat-
ing shunts by whole body scanning compared
with say, the 100 percent oxygen method or the
West-Wagner multiple inert gas method.
DR. GORIS: We use microspheres made of albumin
labeled with technetium 99m. The tracer, whose
size is in the range of 35/, is trapped in the pul-
monary capillaries. We do know that in patients
without vascular shunts, 95±3 percent of the
tracer remains in the lung. If a larger fraction
goes to the systemic side, one assumes that the
tracer found a larger arteriovenous connection.
By quantitating extrapulmonary radioactivity, a
shunt can be calculated.6
DR. ROBIN: Do you have any independent way
of determining the size of the particles? How
much small tail do you have?
DR. GORIS: If you look at the tracer we have
used, you would have 5 percent, which would be
less than 15,, and not many particles larger than
60,u.
DR. ROBIN: And of that 5 percent material of
small tail would it be close to capillary size or is
a substantial fraction below 8,A?
DR. GORIS: There is a certain amount of slough
that we cannot eliminate. We know that in most
patients in whom there is no suspicion of any
kind of shunt, not many spheres go to the systemic
circulation.
DR. ROBIN: Clinically, therefore, we cannot dis-
tinguish between two processes: labelled particles
which are small enough getting through the capil-
laries and that fraction of the cardiac output that
normally goes through anatomical shunts.
DR. GORIS: It is just a coincidence that the cal-
culations happen to correspond so well with cal-
culations based on physiologic methods. Given a
patient with a certain body volume but a variable
body geometry, the lungs and the body generally
contain radioactive particles that are emitting
gamma rays. Some of the gamma rays never
escape because they become trapped within the
body as a result of absorption of the tracer. Quan-
titating gamma ray emission is not the same
process as liquid scintillation counting of a very
small sample whose geometry and absorption are
tightly controlled. In fact, we do not even know
for certain that we count the top portions of the
patient with the same efficiency as we count the
lower portions.
DR. ROBIN: I would like to ask an additional
question. If you are just looking at the lung, how
deep within the lung do you suppose you see with
a ventilation scan? And how deep do you see in
a perfusion scan? My impression is that with
xenon (either 127 or 133) you are looking at an
outer shell of lung tissue because of internal
absorption. Perfusion scans in which you use
higher energy provide deeper representation of
the lung compared with ventilation scans. Are
these fair questions?
DR. GORIS: Those are very fair questions. The
absorption is important. The average patient does
have a certain amount of fatty tissue and muscle
and bone surrounding the lung. Because of in-
ternal absorption, which is more important for
xenon 133 than for technetium 99m, activity in
superficial tissues is relatively better detected with
technetium 99m.
DR. CUMMISKEY: Does that mean that in a fat
person the results are different than in a thin
person?
DR. GORIS: Yet, it does. Absolutely.
DR. ROBIN: So, you make another assumption
that is open to question: you assume the absorp-
tion is homogeneous. That is fine from the stand-
point of homogeneity of one lung versus the other,
but it is not so good in looking at regional
changes. Is that a fair statement to make?
DR. GORIS: That is correct. Now one of the
advantages of 'krypton 81m used for ventilation
scanning is that the energy is exactly the same or
very close to the same as the tracer that is used
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for the perfusion scan (technetium). Comparison
between the two would be more exact.
To go back to the detection of right-to-left
shunting, in a patient without a shunt, activity is
detected in the lung only, and not in the body,
because 95 percent of the tracer sticks in the lung.
In the patients whom we are discussing, you see
a large amount of body, and the kidneys on the
image representing the activity distribution. (If
you do not recognize the kidneys as individual
structures, there is something peculiar going on;
either the patient does not have normal kidneys
or your tracer is not behaving properly.) In the
case of a shunt, the kidneys should be seen very
well, since they get 15 percent of the cardiac out-
put. When I look at the perfusion scan with the
computer, I have to select the region that I will
call the lungs. Even if some extrathoracic regions
are included, the error is not large because even
when only 50 percent radioactivity remains in the
lung (and 50 percent in the rest of the body), a
large fraction of the other 50 percent would still
not be included by making the lung region too
large. I think that I have now reviewed three
types of error: (1) transposing 1:1 an anatomic
observation into a physiological one (for example,
that larger vessels are shunting vessels), (2) as-
suming that the tracer is homogeneous and dis-
tributes itself according to blood flow and (3)
assuming that the measurements are based on an
accurate recognition of anatomical regions that
are uniformly detected.
DR. ROBIN: Can I ask you about one of the
errors? Could filtering be used to eliminate at
least the tail of small particles in order to have
more homogeneous microspheres?
DR. GORIS: Yes, we could do that.
DR. CUMMISKEY: Does not the manufacturer say
that 95 percent of the microspheres fall between
15 and 35,?
DR. GORIS: Yes, something like that. From each
individual batch they take only one sample which
they check and then decide whether it passes
muster. You would have to check each dose
yourself.
DR. ROBIN: It would be inconceivable to me that
you fill all of the pulmonary precapillaries with
particles that were 35- in diameter and that the
patient would survive. So the truth of the matter
is that you only count a fraction of the capillaries.
DR. GORIS: It is estimated as one in 10,000. The
total number of spheres varies between 100,000
and 600,000.
DR. ROBIN: That estimate seems overly precise.
How was it obtained? Has anyone carried out
studies in animals to determine how many of the
gas exchange units in the lung are being occluded
by tracer particles?
DR. GORIS: Yes, studies in dogs have been done
using continuous infusions and determinations of
oxygen saturation at the same time. Before you
can measure alterations of gas exchange in the
lung, you have to inject much more tracer than
we do.
DR. ROBIN: So there is no quantitative estimate of
what fraction of the gas exchange units within the
lung are being seen with a perfusion scan?
DR. HANCE: It must vary remarkably depending
on how sick the patient is.
DR. GORIS: Yes, that is correct. Some patients
are seen who are known to have very low oxygen
saturation values. In these patients injection is
done while we watch the distribution of the tracer
because of two reported cases of death in patients
with massive lung disease who had only a very
small part of their lung perfused. In children and
also in adults who appear cyanotic we do not
inject the usual amount but dilute the tracer by
another factor of ten because we do not want to
embolize the brain.
DR. THEODORE: Basically, therefore, if you got
further and further into the chest, then you would
have a difference in 'terms of the ratio of counts.
DR. GORIS: That is absolutely correct if two
tracers with different emission energies are used.
DR. ROBIN: When I read the original paper pro-
posing ventilation scanning for the diagnosis of
pulmonary embolism (incidentally, the first one
came from Stanford6), my reaction was that aside
from physiological problems, the approach was
unrealistic because of the counting problems that
you point out. Intuitively it seemed that it would
be most difficult to look at a thin rim of tissue
and try to make specific correlations between the
anatomy and the counting. Specifically I thought
that major decreases in ventilation might not be
detected. Is that unfair?
DR. GORIS: No, it is not unfair. We were so much
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aware of the problems that at one time we used
xenon for both the ventilation and the perfusion
in order to have at least the same type of physical
restrictions, because comparison is the key.
DR. ROBIN: How do you go from the raw data to
the results provided as Polaroid pictures?
DR. GORIS: The instrument we use has an oscil-
loscope. The detector detects a little flash on the
oscilloscope screen in view of a Polaroid camera
whose shutters remain open. The problem is cali-
bration. You cannot really use this Polaroid image
to decide whether the shunt is large or not, only
to illustrate a shunt.
DR. PINSKY: So, can you subtract from the Po-
laroid picture?
DR. GORIS: No. Simultaneously the data are
stored in a computer which is used for quantita-
tion.
DR. CUMMISKEY: The second patient this morn-
ing is a 56-year-old man who presented with a
brain abscess in 1969. In 1973 he was admitted
with dyspnea at rest and increased sputum pro-
duction. An x-ray study of the chest showed
numerous nodules throughout the lung fields. A
pulmonary angiogram at that time showed large
A-V fistulae in the right and left lower lobes. Both
these fistulae were resected with a minimum loss
of lung tissue. A pulmonary angiogram done in
the Palo Alto Veterans Administration Medical
Center four years later showed these lesions to
be absent and no other fistulae were noted. Pul-
monary function tests and blood gas studies were
done after surgical operation and showed hy-
poxemia and obstructive lung disease.
DR. ROBIN: So now after operation there is no
evidence of an anatomical pulmonary vascular
shunt by angiography or by scan. However, the
patient is hypoxemic. This case suggests a new
use for the Goris scan. As people get older, and
especially if they are smokers, intrinsic lung dis-
ease develops. That must also be true of those
persons who have pulmonary A-V fistulae. By
using the Goris scan you could distinguish be-
tween patients with persistent vascular shunts and
those with intrinsic lung disease and alveolar
shunts.
DR. THEODORE: Would you discuss that further?
DR. ROBIN: One of the important things about the
concept that there are three kinds of shunt-
alveolar shunts caused by lung disease, pulmonary
vascular shunts and cardiac shunts-is that they
require quite different forms of therapy.7 I have
previously thought statically about these patients.
You find one category of shunt or another in a
patient and the patient remains in a given cate-
gory indefinitely. The data from the second pa-
tient illustrate that one must consider the pos-
sibility of change with the passage of time. Let
us say that a 35-year-old patient has a pulmo-
nary vascular shunt documented by a Goris scan
plus other data, and that you treat the patient
successfully. The patient is a smoker and is subject
to the same kinds of things that happen to lungs
with aging and smoking. Later an alveolar shunt
may develop. When the patient returns hypox-
emic, you say "Oh my God, we didn't remove all
of the pulmonary A-V fistulae and, therefore, we're
going to angiogram the patient and look for re-
sectable areas." Whereas an independent disease
has developed.
DR. CUMMISKEY: And that was the interpretation
in this patient in October 1977.
DR. LYNNE-DAVIES: His referral originated with
a phone call: "We have a man here who is known
to have the Rendu-Osler-Weber syndrome. He
has had previous surgical therapy for it. He did
well for a while, and now is much worse. We
suspect he has other fistulae which must be re-
sected." He was referred to us and the end results
of the workup, in terms of the original disease,
were negative. The management, therefore, was
substantially different. Treatment for chronic
bronchitis was required.
DR. CUMMISKEY: Now, if we can just go back to
the first patient. The issue really is whether to
reoperate to remove additional A-V fistulae. We
ask "Should she be considered now for a pulmo-
nary angiogram with a view to possible opera-
tion?" Or should we take the opinion of 1972,
and say "Well, that is probably the way it still is
five years later."
DR. ROBIN: I think the answer to that is easy.
We should obtain the angiograms of 1972 and
see. If these were technically satisfactory, then I
think you have to assume that the hypoxemia
relates to the known pulmonary vascular shunts.
In addition, our studies suggest that the A-V mal-
formations account for most of the hypoxemia
now. Now, the question of whether it is surgically
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approachable or not depends on what the previous
angiograms showed. If we do not have those data
or the material is not obtainable, then we ought
to determine that we have little to offer except
an operation. The focus of the clinical manage-
ment is on that critical information: What did
the old angiograms show? If they showed inoper-
ability, then we have no right to have new angi-
ograms made. However, if the angiograms are
not available then we have to know whether there
is potentially resectable disease. Simply getting
new angiograms without trying to obtain the old
ones is not acceptable. Pulmonary angiograms
are dangerous and have their own inherent prob-
lems.
DR. CUMMISKEY: Perhaps some of those A-V
fistulae of 1972 have opened up and now may be
possible regions for excision?
DR. LYNNE-DAVIES: If by any standards they
were inoperable in 1972 and since then have
gotten worse, that really does not affect the issue
of management. On the other hand, if the studies
from 1972 are either unobtainable or unsatisfac-
tory for any reason, we do not sufficient informa-
tion. Clearly, we would have to go ahead and
obtain the essential information.
DR. CUMMISKEY: Except it seems now that you
are taking an opinion for a fact; that is, the
operability of the lesions.
DR. ROBIN: We either have to get the 1972 angi-
ograms and look at them ourselves, or we have
to get new ones. But the first thing to do is to try
and obtain the earlier data.
DR. CUMMISKEY: And now a second question:
Is there any place in a case like this or in other
cases of pulmonary A-V fistulae, for doing selec-
tive injections into the areas of the fistulae? What
is the state of the art on that?
DR. ROBIN: You mean to try to obliterate them?
DR. CUMMISKEY: Yes, obliterate them.
DR. ROBIN: I think it would be very dangerous.
But my answer is that I do not know.
DR. CUMMISKEY: Then the third thing, of course,
is that this patient should probably be given oxy-
gen.
DR. ROBIN: Yes, I would like to discuss that in
a moment.
DR. THEODORE: That raises some questions too.
DR. GORIS: 1 would like to mention a small point:
If your surgeon now looks at the old data, he
then has an answer whether he would have oper-
ated based on that information. If one of those
lesions has now become three times as large,
then it is not only a question of technical feasi-
bility but how "attractive" it looks to him.
DR. ROBIN: But we would have a voice in making
that decision. In this type of case there is little
accumulated experience. Our surgeon may look
at the angiograms and indicate one large fistula
and say "I feel confident that I should operate."
And I may look at it and say "Yes, but look at
the other 98 lesions. As you remove more lung
tissue, you are going to increase pulmonary vas-
cular resistance and the other ones are going to
get larger. I do not think you should operate."
Then we would reach some consensus based on
best guess on how to manage the patient.
What I would like to do now is to indicate
some of the. questions that are unanswered in
patients who have pulmonary vascular shunts. It
is more or less settled that determining the dif-
ference between alveolar shunts and pulmonary
vascular shunts can provide important informa-
tion. One simple thing that we do not know is
the prevalence of pulmonary vascular shunts. No
one has any idea of the frequency of the occur-
rence of pulmonary vascular shunts in various
patient populations. The general view until now
has been that pulmonary vascular shunts are un-
common. Clinically important pulmonary vascu-
lar shunts were essentially limited to two circum-
stances: (1) the Rendu-Osler-Weber syndrome
and (2) sporadic pulmonary A-V fistula, unas-
sociated with either a hereditary component or
with A-V fistulae occurring elsewhere in the body.
At present we do not even know the prevalence
of A-V communications in liver disease. It is to
be hoped that, over the course of the next two
years, Drs. Salfen and Rushing will give us a
better estimate of how common this is in liver
disease. There are a number of other disorders
in which it is reasonable to speculate that signifi-
cant pulmonary vascular A-V shunting is present.
One of these is pulmonary hypertension. Patients
with severe primary pulmonary hypertension not
uncommonly have substantial degrees of hypox-
emia-not easily accounted for by abnormal
parenchymal lung function. In some of these
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patients, hypoxemia develops as a result of right-
to-left shunting in the heart, say through a pa-
tent foramen ovale. In other patients, who seem
to have substantial degrees of hypoxemia, that
explanation is not tenable, at least judging by
angiographic or catheterization studies. If the
Goris scan can provide insight into prevalence,
then it would provide an important addition to
our understanding of pulmonary hypertension.
DR. HANCE: However, these patients would be at
increased risk from perfusion scanning.
DR. ROBIN: You would have to try to estimate
the possible value of the procedure against the
possible risk in individual patients. All I am
saying is that cardiac catheterization and angi-
ograms have a greater risk in all probability than
perfusion scanning. The second group of patients
who often have hypoxemia, the mechanisms of
which are not completely defined, are patients with
pulmonary embolism.* There are two possibilities
to explain the development of direct A-V com-
munications in these patients. One, which was
first raised at least 35 years ago, is that in the
normal lung there may be direct A-V communi-
cations. The reason that these are not -the sites of
shunting is that the pressure relationships are
such that blood flow through them is small in
normal persons. Now, with pulmonary embolism,
shunts might open up not de novo, but because
of a new set of pressure-volume flow relation-
ships within the lung vasculature. The second
possibility is that somehow with acute pulmonary
hypertension, new vascular shunts develop. The
third disease (or group of diseases) in which
there is occasionally hypoxemia not explained
easily by the kind of measurements commonly
available is pulmonary carcinoma or, more ac-
curately, pulmonary malignant lesions. Work
conducted by Folkman suggests that there are
humoral agents elaborated by tumor cells (capil-
lary angiogenic factors) which cause the develop-
ment of new vessels.8
I have seen two patients who were shown to
have substantial A-V communications within the
lung. One had Hodgkin disease of the mediasti-
num and the other had bronchogenic carcinoma.
Each had hypoxemia of unknown cause. The basis
of the abnormal A-V communications was not
clear.
*The major mechanism is known. It is the development of
regional hypoventilation in areas that are perfused.
DR. HANCE: Demonstrated by?
DR. ROBIN: Demonstrated during surgical pro-
cedure. I would speculate that with some tumors,
important A-V communications may develop in
the lung, and the possibility of vascular shunts
should be considered in patients with hypoxemia
of unknown cause.
A second important problem involves the regu-
lation of lung shunt vessels; that is, determining
the physiological mechanisms that modulate pres-
sure, volume and flow in these vessels. The
amount of flow through the shunt vessel, as com-
pared with the normal pathway, will vary as a
function of the resistance through the two path-
ways. If, in patients who have pulmonary A-V
shunts related to liver disease, one measures pul-
monary vascular resistance after administering
low oxygen mixtures, no increase in pulmonary
vascular resistance is noted. In a normal person
there is an increase in pulmonary vascular resist-
ance.9 The workers who showed this considered
the phenomenon to be a "failure of pulmonary
vasoconstriction." In other words, as alveolar
oxygen pressure decreased in patients with pul-
monary vascular shunts, you did not evoke what-
ever it is that produces pulmonary vasoconstric-
tion and, therefore, pulmonary vascular resistance
did not increase. Having analyzed their data 1
think they show that as you lower Pao2, by ad-
ministering low oxygen mixtures to breathe, you
vasoconstrict normal pulmonary arterioles. This
increases flow through the low resistance shunt
vessels and pulmonary vascular resistance is not
increased. Therefore, I believe it is probable that
there is a mechanical rather than a chemical
explanation for failure of pulmonary artery pres-
sure and pulmonary vascular resistance to rise.
One important physiological question is what
happens then to the resistances in the normal
and the shunt pathways as a result of low alveolar
oxygen tensions. Another is whether it is possible
that these communications actually respond to
physiologic and pharmacologic stimuli like sys-
temic vessels rather than pulmonary blood ves-
sels? As you know, in systemic vascular beds, if
you drop the oxygen pressure vasodilatation
occurs. Is it possible then that as you drop alve-
olar oxygen pressure, you are not only vasocon-
stricting normal vessels, but you are vasodilating
the shunt vessels? Should it turn out that the
shunt vessels do act like systemic vessels, then is
it possible that they respond like systemic ves-
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sels to other kinds of pharmacological agents
like beta-adrenergic-agonists and alpha-adrenergic-
agonists. By administering these agents could you
selectively produce vasoconstriction of the shunt
vessels and, therefore, force more blood through
the normal pathway? Even if the beta agonists
increased resistance in both pathways, but selec-
tively increased resistance more in shunt vessels
than in normal vessels, you could decrease the
volume of shunting in the patient, and improve
gas exchange. The whole question of the response
of shunt vessels to pharmacologic agents, as well
as to oxygen, is an important one.
In the first patient, it might be useful to main-
tain alveolar oxygen pressure at the highest levels
possible. Maintaining a high oxygen pressure
might prevent, in many regions, alveolar hypoxia
and, therefore, would tend to keep the resistance
in the normal pathway as low as possible. A trial
of oxygen administration during the time she
sleeps might be warranted for this purpose.
DR. HANCE: We have no reason to think that
her alveolar Po2 is low, though. It is not in a
range in which oxygen therapy normally would
be needed.
DR. ROBIN: That is only mean alveolar Po2. We
do not know what is happening regionally.
DR. HANCE: But we have no reason to suspect
that it is bad.
DR. LYNNE-DAVIES: There are two aspects to it.
I think that, as far as the shunt you have dis-
cussed, one can speculate on two or three things.
First, it must be behaving differently than the
others because it is a shunt vessel, and presumably
exposed to much lower oxygen pressures going
into it and coming out of it than vessels in the
main transit. On the other hand, you might be
right that it is behaving like a systemic vessel. An
alternative possibility is that it is maximally vaso-
constricted and is behaving like a pulmonary
vessel. It could still have the same controlling
mechanisms but, because throughout its course
there is a continuously low oxygen tension, it
might behave much differently.
DR. ROBIN: I am making the assumption that
vasoconstriction does not take place in the capil-
lary but in precapillary vessels, and that the
normal vessels, precapillary vessels and shunt
vessels are exposed to a low oxygen pressure.
DR. HANCE: But in the patient who has a normal
alveolar oxygen level, the blood coming into the
pulmonary capillary is low in oxygen.
MR. VAN KESSEL: Are you postulating that the
shunt is proximal to the constriction? In other
words, there would be a difference whether or
not the shunt vessel with vasoconstrictors is a
matter of hypoxemia or whether or not the shunt
would take off proximal or distal. That could
still be right, depending on where you place the
shunt.
DR. LYNNE-DAVIES: I agree with Dr. Hance, in
a sense, about high alveolar oxygen pressure in
areas adjacent to the normal vessels. However, I
am not quite sure, taking your model, how in-
creasing it would alter vascular resistance.
DR. ROBIN: Suppose, for example, that by using
high oxygen you increase her mixed venous oxy-
gen pressure from 40 to 50 or 55 torr. Now, the
control of these vessels, if they are systemic ves-
sels, will not depend on what is happening to
alveolar oxygen pressure. It will depend on what
is happening to precapillary oxygen pressure.
High oxygen tensions do vasoconstrict systemic
arterioles. High oxygen tensions probably vaso-
dilate pulmonary precapillaries. I would be de-
lighted to improve arterial oxygen pressure by
any combination of shunt vasoconstriction and
pulmonary vascular vasodilatation.
DR. LYNNE-DAVIES: Even if we accept the first
two possibilities, it then seems to me that you
said "Well, let's see how she does with oxygen
at night and so forth." Looking at the blood gas
values, the most crucial time for her to get oxy-
gen would appear to be when she is standing up.
DR. ROBIN: Do you consider that your objections,
which are more or less theoretical, are sufficiently
strong in your mind so that you would not try
oxygen?
DR. LYNNE-DAVIES: No, they are not sufficiently
strong that I would not try oxygen.
DR. ROBIN: Perhaps a summary of the confer-
ence might be worthwhile. We have discussed
two cases of patients with pulmonary A-V com-
munications. The first teaches us that these com-
munications may be so large and diffuse that
curative surgical procedures may not be possible.
The second teaches us that even after curative
surgical therapy, the patient is not immune to the
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development of more common forms of lung
disease. This may be mistaken for a recurrence
of A-V communications.
We have also discussed a number of other
points: (1) the application of Ockham's razor to
clinical medicine, (2) the causes of cerebral dis-
ease in patients with right to left shunts, (3) the
effects of position and exercise on gas exchange
in the lung, (4) the use of the Goris scan in
detecting and quantifying the lung vascular shunts,
(5) the technical limitations of ventilation and
perfusion lung scanning, (6) therapeutic ap-
proaches to pulmonary A-V communications and
(7) the physiological regulation of shunt vessels
in the lung.
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Nutritlonal and Metabolic Significance of
End Portion of Small Bowel
A SIGNIFICANT DEVELOPMENT in recent years is the recognition that just as the
proximal portion of the small bowel is essential in the matter of absorption,
digestion and nutrition, so the last part of the small bowel is vital to our nutri-
tional and metabolic status. And the last part of the small bowel is not an inert
muscular tube; it is a vital structure. When it is resected for disease, there may
be alterations in the recycling of bile salts and this will lead to a reduced bile
salt pool. This, in turn, will interfere with absorption of fat; it will also lead to
alterations in the bile salt biochemistry and lead to an increased incidence of
gallstones. And so, as part of your workup, in my opinion, you should include
a cholecystogram every so often, because there are at least two studies in addition to
ours that suggest that there is an increased incidence of gallstones in these patients.
-JOSEPH B. KIRSNER, MD, Chicago
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